ROP treatment by year in individual participants for the entire cohort (<28 weeks GA)
| Network | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | p Trend | p Trend excluding 2007 |
|---|---|---|---|---|---|---|---|---|---|
| ANZNN | 71 (8.2) | 72 (8.3) | 58 (7.4) | 46 (6.1) | 64 (7.8) | 57 (6.9) | 56 (6.6) | 0.13 | 0.26 |
| CNN | 88 (14.8) | 86 (13.2) | 70 (10.8) | 91 (11.6) | 71 (9.8) | 67 (8.8) | 64 (8.9) | <0.01 | <0.01 |
| INN | 38 (13.9) | 35 (13.0) | 33 (11.4) | 24 (7.8) | 31 (10.7) | 24 (9.3) | 25 (8.3) | 0.01 | 0.08 |
| NRNJ | 431 (36.4) | 311 (26.2) | 381 (30.5) | 424 (30.7) | 402 (29.5) | 439 (31.4) | 352 (28.0) | 0.03 | 0.35 |
| SNQ | 26 (12.8) | 21 (11.3) | 23 (11.1) | 30 (13.9) | 25 (13.5) | 18 (7.9) | 17 (6.6) | 0.02 | 0.05 |
| SwissNeoNet | 5 (4.0) | 7 (4.7) | 6 (4.2) | 12 (7.3) | 5 (2.8) | 6 (3.1) | 6 (3.9) | 0.49 | 0.34 |
| SEN-1500 | 65 (14.7) | 54 (11.5) | 64 (12.5) | 77 (15.8) | 65 (13.3) | 66 (12.4) | 65 (13.2) | 0.83 | 0.68 |
| UKNC | * | 59 (5.2) | 61 (5.5) | 138 (9.2) | 148 (8.8) | 142 (8.3) | 195 (11.9) | <0.01 | <0.01 |
| FinMBR | 11 (12.1) | 8 (7.6) | 19 (20.7) | 8 (9.1) | 14 (12.3) | 11 (11.5) | 7 (9.1) | 0.70 | 0.68 |
| TuscanNN | * | * | 8 (13.3) | 4 (8.2) | 5 (10.2) | 4 (7.7) | 6 (10.3) | 0.59 | 0.59 |
| Total | 735 (19.4) | 653 (13.0) | 723 (14.2) | 854 (14.9) | 830 (14.1) | 834 (13.7) | 793 (13.7) | <0.01 | 0.95 |
*Data not available.
ANZNN, Australia and New Zealand Neonatal Network; CNN, Canadian Neonatal Network; FinMBR, Finnish Maternal Birth Register; GA, gestational age; INN, Israel Neonatal Network; NRNJ, Neonatal Research Network of Japan; ROP, retinopathy of prematurity; SEN1500, Spanish Neonatal Network; SNQ, Swedish Neonatal Quality Register; SwissNeoNet, Swiss Neonatal Network; TuscanNN, Tuscan Neonatal Network; UKNC, UK Neonatal Collaborative.